AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 121 min read$QURE

O'Keefe Kylie sold $431K of QURE

O'Keefe Kylie (Chief Customer & Strat Officer) sold 15,936 shares of uniQure N.V. (QURE) at $27.06 ($0.43M total) on 2026-06-11.

Original reporting
SEC EDGAR · O'Keefe Kylie
Published Jun 12, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$QURE
Bearish
medium confidence
Mentioned
$QURE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QUREBearishLow
01

Why it matters

The newest fact is the disclosed open-market sale by a named officer; absent any other corporate catalyst, it mainly affects short-term sentiment rather than valuation drivers.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to materially change the fundamental outlook.

03

What to watch

The article doesn’t provide context on total insider holdings, prior sales cadence, or whether other insiders/large holders are buying—so the signal may be noisy.

Relevance 4/10Novelty 6/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QUREBearishMedium confidence
Context

uniQure insider O'Keefe Kylie (Chief Customer & Strat Officer) sold 15,936 shares on 2026-06-11 at $27.0600 via open-market sale.

Expected impact

Near-term sentiment drag is possible, but magnitude is likely limited given it’s a single officer sale and no 10b5-1 plan is cited.

Evidence & confidence

The filing is primary-source (SEC Form 4) and the direction is sell, but the article provides no accompanying company-specific news (earnings, trial, guidance, deal, or enforcement) that would reset fundamentals.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; without a 10b5-1 plan disclosed here, the sale still may not reflect a bearish view on the pipeline.

Key entities

  • issuer
    uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    O'Keefe Kylie

    Chief Customer & Strat Officer who sold 15,936 shares.

  • filing
    SEC Form 4

    Primary-source insider transaction report.

Read at source← All news

Related articles

AUG 8
$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

aol.com8 min
AUG 6
$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

fabrydiseasenews.com5 min
JUL 29
$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

investing.com6 min
JUL 29
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

finanznachrichten.de6 min
JUL 29
$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

SEC EDGAR 8-K6 min
JUN 25
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.

finanznachrichten.de2 min